Abstract: Arteriosclerosis obliterans (ASO) or peripheral artery disease (PAD) is among one of the most common medical concerns that is
METHODOLOGY
We made this review by systematically searching relevant literatures using multiple keywords and standardized terminology on NCBI Pub MED, Google Scholar and the other scientific website and international journals for publications describing randomized controlled trials (RCTs), Case presentation, and Original article related to the topic of our study.
Claudication Questionnaire appeared to be 91% specific and 99 % sensitive in patients with intermittent claudication. [5] PAD is thought out as to be a set of chronic or acute syndromes due to arterial occlusion, commonly affect the lower limb vessels. Ischemia of the lower limbs can be classified as functional state that occurs when the blood flow is normal at rest but insufficient with the increase demand during exercise. Critical ischemia is produced when the reduction in blood flow results in a perfusion deficit at resting stage. The pathophysiologic mechanism of arterial insufficiency is based on the presence of arterial stenosis. An imbalance between the demand and supply of blood to peripheral tissues more or less abruptly cause a situation of acute ischemia of thrombotic origin. High risk plaques found in the arteries of the lower limbs are very stenotic, fibrous [6] and hypercoagulable. These lesions are composed of a large extracellular lipid nucleus and abundant foamy cells, covered by a fibrous layer which bears a risk to be ruptured. [7] This mechanism results in thrombosis that obliterates the vascular luminal patency. PAD causes the Muscles in these areas work twice as hard, during motion or at rest. Once PVD is suspected, ankle brachial index (ABI) testing should be performed, ABI less than 0.9 is consistent with PVD. However, this test will not exclude proximal aneurysms or arterial disease that is distal to the ankle. [8] Clinical evaluation of intermittent claudication is mostly based on WHO/Rose questionnaire or the self-administered Edinburgh Claudication Questionnaire. [9, 10] Laboratory evaluation includes: complete blood count with platelet count, fasting glucose or A1C, fasting lipid profile, serum creatinine, and urinalysis for glucosuria and proteinuria [11] beside this elevated levels homocysteine, C-reactive protein, and lipoprotein are risk factors for PVD. Duplex ultrasonography, magnetic resonance arteriography, and angiography are used to determine lesion localization, when invasive or surgical procedure is possible. [12] PVD can be monitored by the degree of pain, walking distance, repeat ABI testing or evaluation by specialized center. Claudication may even progress to acute or critical limb ischemia; though the risk is less than 1% per year. [13] Potent risk factors for PAD and IC are: Smoking, Hypertension, Diabetes, Lipid abnormalities, Increased LDL-cholesterol, Elevated triglycerides, HDL-cholesterol, Elevated homocysteine, Age, Increased fibrinogen and blood viscosity, sex , Lipoprotein(a), LDL (low-density lipoprotein) and HDL (high-density lipoprotein). Studies had shown a high degree of overlap between PAD and cardiovascular disease; the latter has been diagnosed in 29% of patients with PAD compared with only 11% without PAD. [14] Depending on the diagnostic technique used, cardiovascular disease can be detected in as many as 90% of patients with intermittent claudication. [15] In a Swedish study of 439 men, an ankle-brachial index of less than 0.9 was associated with a 2.4-fold higher mortality rate and a two folds higher cardiac event rate. [16] Other studies also revealed up to 2-4 fold increase mortality risk in patients with intermittent claudication, predominantly from cardiovascular disease. [17] The severity of IC symptoms is commonly scored by Rutherford-Baker's or Fontaine classification schemes. IC lesions are mostly located in the femoropopliteal arteries (70%) with the remainder in the aortoiliac arteries. [18] Age is the most important, nonmodifiable risk factor for PAD, with a prevalence of 0.9% in people under age 50 and 23.2% in people over the age of 80. Ethnicity and sex is also important factors, with the highest prevalence of PAD seen in African American men and women (prevalence 19.2%) and Hispanic women (prevalence 19.3%). [19, 20] Prevalence of PAD in men is greater than women. Several important modifiable risk factors have also been greater identified. [21, 22] The association between smoking and PAD is unavoidable, the risk of PAD in smokers is proportional to the number of cigarettes consumed. [23, 24] PAD is about twice as common in diabetic patients as it is in non-diabetics. Furthermore, for every 1% increase in hemoglobin-A1c, there is a 28% increased risk of developing PAD , beside this total cholesterol level greater than 270 mg/dL, elevated ratio of total cholesterol to high-density lipoprotein (HDL), low HDL levels, and hypertriglyceridemia. Smoking magnifies the contribution of dyslipidemia in PAD. [25] Hypertension is associated with cardiovascular disease but is not as strong a risk factor for PAD as smoking and diabetes. In asymptomatic PAD patients, hypertension increases chance of developing symptoms. The increased risk is 2.5-fold in men while in women it is 3.9-fold. [26, 27] In several studies dyslipidemia have been found to have an association with PAD and IC. Patients with renal disorders, especially postmenopausal women with a history of CAD, are found more susceptible to develop PAD than those with CAD who have normal renal function.
with PAD, 30% of whom have elevated homocysteine level .This is less intuitive but intriguing the association of C-reactive protein with PAD. [31, 32] Recent studies have shown that asymptomatic patients with high CRP level are more susceptible to develop symptomatic PAD over a period of 5-year, than age-matched controls in whom CRP is not elevated. Among normal CRP level patients, those with a level is in the top quartile (of the normal range) are more susceptible to develop PAD as compared to those whose CRP level is in the bottom quartile (of the normal range). [33] Common approaches to treatment of PAD and IC include: Modification of Life-style, Smoking cessation, Diet for weight loss and lipid altering, Supervised and unsupervised exercise programs, Pharmacotherapy, Re-vascularization, Endovascular treatment (PTA with or without Stanting) and Surgery Plus Co adjuvant Medical Treatment. Approved Risk-reducing agents are: Antiplatelet drugs(ie) aspirin, ticlopidine, clopidogrel, cilostazol and Lipid-altering drugs (ie) fibrates, niacin, statins (simvastatin, lovastatin, pravastatin, atorvastatin), bile acid sequestrants. Some of the Agents under study are: Propionyl-l-carnitine, prostaglandin drugs, angiogenic growth factors, l-arginine. Approved drugs for treatment of intermittent claudication: Cilostazol, Pentoxifylline. The medical therapy for PAD is basically aimed to achieve increased walking distance, and secondary prevention of cardiovascular event.
Invasive therapy include: Endovascular treatment, PTA with balloon dilatation with or without stenting and Open Revascularization surgery. Medical treatment of patients with PAD has 2 objectives. The first is to improve the functional situation of the limb. Secondly, prevent events secondary to the multifocal distribution of the disease. Patients with symptomatic PAD are known to have a very poor long-term prognosis, with an increase risk of 10-year mortality, 15 times higher than patients without PAD. [34] Supervised programs of physical exercise has been proven highly effective and plays an important role in improvement Intermittent claudication. These programs also affect risk factors, endothelial function, and hemorrheologic markers. [35] Surgical treatment (Conventional or endovascular) of PAD depends on the clinical situation of the patient and the vascular bed that requires reconstruction. It may need more than one surgical procedure depend on the sector of reconstruction. The indication for intervention should also include an evaluation of the particular surgical technique required revascularization surgery. Diffuse, extensive involvement is usually best treated by placement of an aortic unifemoral or bifemoral prosthesis (Figure 1, 2) . The effects of this well-systematized technique are variable. The results in terms of permeability are above 85% and 80% at 5 and 10 years, with operative mortality below 5%. However, the technique involves major arterial surgery and requires quantifying the surgical risk to select the most suitable candidates.
Figure1. Arteriography Showing Extensive Aortoiliac Occlusion and the Result after Aortobifemoral Bypass Surgery

Figure2. Image of Dacron Prosthesis with Infrarenal Anastomosis
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Angioplasty is the technique of mechanically widening of narrowed or obstructed arteries, initially described by Charles Dotter. Angioplasty provides the best results in short lesions, preferably stenosis and non-calcified lesions. Its long-term results in these situations are good, with permeability figures of 70% at 5 years for patients with claudication. [36] The advantages of implanting a stent have been assessed in clinical trials, with comparatively better permeability figures in systematic stenting as compared with simple balloon angioplasty. [37, 38, 39] The best approach is probably to implant a stent selectively in those patients in whom balloon angioplasty shows an initially suboptimal result ( Figure  3 ). In general, we can say that short lesions, less than 10 cm, preferably with stenosis, are the most suitable for endovascular treatment. [40, 41, 42, 43] In longer lesions, the use of expanded polytetrafluoroethylene coated stents seems to provide advantages over the other methods, though randomized studies with a greater follow-up are required. [44] In surgery plus combined with adjuvant medical treatment, prior to open or endovascular surgery an indefinite program of anti-aggregation is necessary. The use of anti-aggregating drugs has proved greater result in patients with a venous bypass as compared with prosthesis, especially in the infrainguinal region. [45] In a Cochrane review, 41% reduced risk of graft occlusion was found (12 months of follow-up) in patients treated with acetylsalicylic acid following revascularization surgery. [46, 47] Although in patients with coronary disease double anti-aggregation is often used in accordance with the results obtained. However, no conclusive information is available regarding its usefulness in PAD.
Figure3. Arteriographic Image of an Occlusion of the Primitive Iliac Artery and Stenosis of External Iliac Artery, Resolved by Implanting a Coated Stent
DISCUSSION
In order to decrease the incidence rate of perioperative complications and mortality, as well as the scope of anaesthesiological support and duration of in-hospital treatment and diminishing the operative wound all these goals can be achieved by means of minimally invasive interventions. PAD encompasses arterial disorders except the coronary vasculature, but in most guidelines it is limited to branches of the lower aorta. [48, 49, 50] In compared to open surgical revascularization ( Figure 5 ) for PAD, PTA is a better choice for the treatment infrainginual disease of critical limb ischemia, limited life expectancy, lack of an adequate venous conduit and multiple surgical comorbidities. [51, 52] Several studies have established lower peri-procedural mortality and morbidity and high technical success for PTA. Therefore infrapopliteal artery angioplasty is the "first line" therapeutic approach, particularly in high-risk critical limb ischemia (Figure 4 ) (CLI) patients. [53, 54, 55] In diabetic patients extant and burden regarding infrapopliteal arterial diseases are well described in different literatures [56] , more over high post-PTA restenosis rates have also been consistently reported. [57, 58, 59] The impact of high infrapopliteal vessel restenosis rates are not clear on the prognosis of CLI patients, despite regarding high infrapopliteal PTA restenosis rates, the limb salvage rates appear more acceptable [60] when compared to open lower limb bypass. [61] Thus, there is an evolving impression, endorsed by societal guidelines [62, 63] that favors potential near-term benefit of PTA as the "first line approach" in specific CLI patients in comparison to open surgery. Recent data suggest more distal target anastomosis in patients who experienced tibial PTA restenosis, subsequently underwent a lower limb bypass [64] and had higher 1-year amputation and graft closure rates [65] when compared to patients without prior PTA. Likewise, the BASIL trial investigators observed worse amputation-free survival (AFS) rates in patients undergoing bypass after a failed PTA than those undergoing primary bypass [66] Long term follow up of CLI patients show high tibial PTA restenosis rates, that may require lower extremity
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bypass associated with higher bypass failure rates and worse outcomes. [67] Paclitaxel drug-eluting balloons by reducing neointimal proliferation, promote arterial patency. In prospective clinical trials In relatively small CLI patient cohorts, tibial vessel drug-eluting balloon (DEB) angioplasty significantly reduced restenosis rates and late lumen loss (LLL) at 3, 6, and 12 months [68, 69] Although these angiographic assessments were not core lab adjudicated, there is a growing perception that the clinical results of DEB tibial angioplasty mirror the clinical experience in the superficial femoral artery. [70, 71, 72, 73] Ankle-brachial index (ABI) test is recommended screening test for early diagnosis of PAD in patients with signs and symptoms of lower extremity ischemia. An ABI <0.9 with values from 0.91 to 1.0, consider as borderline abnormal. [74] An ABI >1.0 is normal, although ABI >1.4 is typical in PAD patients with calcified, non-compressible lower extremity arteriopathy. The presentation, evaluation, and medical management of PAD are covered by earlier reviews and published guidelines by the American Heart Association and American College of Cardiology. [75, 76, 77] An ABI <0.9 requires close clinical surveillance because it is also an indication of other cardiovascular disease, require intensive secondary prevention measures and monitoring for the onset of symptoms, that may be gradual. [78, 79] 
Figure4. Foot Wound Caused by Ischemic Rest Pain and Tissue Loss (Critical Limb Ischemia)
Figure5. An Intraoperative Photograph of a Right Femoral to Posterior Tibial Artery Bypass using the Greater Saphenous Vein to Correct Peripheral Arterial Disease
Technological improvements in endovascular revascularization equipments have increased options for complex lesions. Though, the longer lesions are more consistently associated with restenosis. [80] For the low risk endovascular techniques, stents are an attractive and feasible treatment strategy. Surgical revascularization is preferred in the common femoral or popliteal arteries. Because these regions may increase stent fracture due to greater compression, torsion, and stretch associated with movement. A single-center series suggest treatment comprised of PTA with provisional stenting is associated with acceptable 12-month results. [81] Endovascular approaches without stenting in these regions include atherectomy and balloon angioplasty alone. DCB with adjunctive atherectomy may address some issues associated with stent placement in these segments even though flow-limiting dissections, recalcitrant recoil, or residual disease would still limit this approach. [82] Intermittent Claudication (IC) represents a progression of arterial obstruction caused by obstructive PAD causing ischemia. In contrast to both CLI and ALI the timing or need for revascularization in claudication is largely dictated by lifestyle limitation. Although IC patients are at low risk for limb loss, however diabetes increases this risk. [83, 84, 85] In focal aortoiliac disease, it is proved that balloon angioplasty alone provides excellent long-term patency with provisional stent placement for good result. The Dutch Iliac Stent Trial comparing stenting with balloon angioplasty and provisional stenting resulted in comparable clinical outcomes, although this may have been caused by relatively low complexity Trans Atlantic Society Consensus. [86, 87] Due to increased recoil seen with ostial iliac disease, the use of primary stenting has been increased for aortoiliac disease. [88] Primary stenting shows high patency rates in a meta-analysis study on 958 total patients suffering from more complex aortoiliac disease. [89] Limitations of comparing different studies related to stenting for occlusive aortoiliac disease include i.e. complexity of disease, the differing segments of iliac artery to be treated, and the use of either balloon-expandable or self-expanding nitinol stents. [90, 91] Currently there are no randomized data available regarding comparing outcomes of aortoiliac stenting with these 2 types of stents. Self-expanding stents are good to avoid arterial rupture. The Cordis Randomized Iliac Stent Project (United States) trial showed same outcomes after iliac stenting with either nitinol or stainless steel self-expanding platforms. [92] Restenosis remains the primary limitation of aortoiliac stenting. Experience derived from stenting with covered stents raised several concerns. Some studies regarding femoral and iliac arteries show similar rates of restenosis to non-covered stents at 12 months. [93, 94] Thrombotic occlusion of covered stents occurred in 10% of cases within 30 days of raising concerns over the long-term risks of stent thrombosis has been also reported. [95] Covered stents do not solve the problem of restenosis, but shift its pattern to edge-restenosis especially in oversized stent. The Covered Versus Balloon-Expandable Stent Trial (COBEST) observe a higher patency rate with covered stent in comparison to non-covered stents in aortoiliac disease; however, non-covered stent group show unusually high restenosis rate. [96] Balloon-expandable stents are mostly used to revascularize IC and isolated occlusive aortoiliac disease. "Self-Expanding Stents" are mostly made of Nitinol, it possess thermal shape memory and are more resilient to mechanical stresses by expanding on deployment at body temperature and then re-expanding after external radial compression. Recently, the Complete Self-Expanding trial that used a new Nitinol self-expanding stent to treat femoropopliteal disease demonstrated a low rate of target lesion revascularization (TLR) and no stent fractures at 12 months. The Supera Interwoven Nitinol Stent Outcomes in Above-Knee Interventions (SAKE) study also showed high rates of patency at 6 and 12 months with no stent fractures Furthermore, the outcomes after popliteal stenting with the Supera stent from the Leipzing Supera popliteal artery registry showed 6-and 12-month primary patency rates of 94.6% and 87.7%, respectively, with a significant increase in mean ABI (0.58 versus 0.97; P<0.001) and no radiographic evidence of stent fracture at 15 months.
Restenosis remains one of the major limitations associated with long segments of SFA stenting, and stimulated the development of "drug-eluting stents". Recently, the Zilver PTX trial compared 24-month outcomes between a self-expanding stent eluting paclitaxel to balloon angioplasty alone. [97] Although this study had a high crossover rate to stenting in the balloon angioplasty arm, all the patients receiving bail-out stenting in this arm were randomized to drug-eluting stents (DES) or baremetal stents (BMS).In comparison with the angioplasty only, the primary DES group demonstrates higher primary patency with the DES (74.8% versus 26.5%) at 2 years. The provisional DES group also demonstrates superior primary patency compared with the provisional BMS group (83.4% versus 64.1%). A French study of the budgetary impact of using the more costly Zilver PTX stent showed net cumulative savings of €6 807 202 over 5 years by reducing the need for future re-interventions.
[98] The use of "Covered self-expanding stents" for the obstructive femoropopliteal disease has been investigated to minimize the incidence of in-stent restenosis. An early trial of patients with symptomatic SFA disease randomized to either Viabahn stents or balloon angioplasty showed ultrasound-assessed primary patency (65% versus 40%) and clinical improvement were better in the stent group. [99] More recently, the Viabahn Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion Superficial Femoral Artery Occlusive Disease (VIBRANT) trial randomized patients with symptomatic complex lesions to Viabahn or conventional self-expanding stents and showed that ultrasound-assisted primary patency was low and not statistically different between the groups (53% versus 58% at 12 months and 24.2% versus 25.9% at 36 months), despite higher stent fracture in the uncovered stent group (50% versus 2%).
[100]
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A recent innovation "Drug-Coated Balloons" (DCBs) has potential benefits applicable to endovascular therapy. Preclinical validation studies have suggested that homogenously distributed drug delivery can be achieved with DCB. [101] The Paclitaxel-Coated Balloons in Femoral Indication to Defeat Restenosis (PACIFIER) trial also demonstrated improved end points for DCB versus conventional angioplasty at 12 months. [102] More recently, the Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis (LEVANT I) trial demonstrated significantly decreased mean late lumen loss for de novo SFA disease treated with the lower paclitaxel dose Lutonix DCB versus conventional balloons in patients treated with either angioplasty only or after stenting. [103] The Drug-Eluting Balloon in Peripheral Intervention for The Superficial Femoral Artery trial randomizing patients to upfront DCB or conventional angioplasty followed by stenting demonstrate similarly encouraging results at 12 months. [104] Most studies of infrapopliteal revascularization include more CLI than IC patients, [105, 106] and IC alone is an uncommon indication. More recent trial data on infrapopliteal revascular-ization with DES are generally geared toward ascertaining important CLI outcomes rather than the relief of IC symptoms. The complexity of the infrapopliteal vasculature, and the technical demands of below-the-knee interventions, infrapopliteal revascularization is usually reserved for CLI only and is not currently recommended for the routine treatment of IC.
CONCLUSION
PTA and primary stenting of the lower limb vessels for management of atherosclerosis Obliterance can be performed safely in early and in advanced peripheral artery disease. The results seem to be an improvement over those of balloon angioplasty alone when compared with published literatures. In the intermediate term, treatment of peripheral artery disease by primary Implantation of a selfexpanding stent yielded results that were superior to those with the currently recommended approach of balloon angioplasty. This reduces the chance of re-occlusion and thus reduces the morbidity and provides a better patient outcome. In conclusion, PTA with stenting is a feasible, safe, and effective procedure for the treatment of CLI. Initial technical and clinical success rates were high, and procedural mortality and complication rates were low. In long-term results, most of the study data demonstrated a 76% assisted primary rate, an 80% secondary patency rate, and an 89% limb salvage rate at 5 years: the high limb salvage rate was attributed to the high assisted primary and secondary patency rates despite the low primary patency rate.
